MedPath

Survodutide

Generic Name
Survodutide
Clinical Trials
Related News

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
Drug: Placebo matching survodutide
First Posted Date
2023-12-19
Last Posted Date
2025-01-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
274
Registration Number
NCT06176365
Locations
🇯🇵

Shimamura Kinen Hospital, Tokyo, Nerima-ku, Japan

🇯🇵

Chiba University Hospital, Chiba, Chiba, Japan

🇯🇵

Hosokawa Surgery Clinic, Aichi, Nagoya, Japan

and more 25 locations

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2023-10-11
Last Posted Date
2025-04-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
5550
Registration Number
NCT06077864
Locations
🇺🇸

AMR Mobile, Mobile, Alabama, United States

🇺🇸

Mobile Heart Specialists, PC, Mobile, Alabama, United States

🇺🇸

The Institute for Liver Health, LLC, Chandler, Arizona, United States

and more 530 locations

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Phase 3
Active, not recruiting
Conditions
Obesity
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2023-10-04
Last Posted Date
2025-02-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
756
Registration Number
NCT06066528
Locations
🇬🇧

Bradford on Avon Health Centre, Bradford on Avon, United Kingdom

🇬🇧

Mounts Bay Medical Limited, Hayle, United Kingdom

🇨🇳

Pingxiang People's Hospital, Pingxiang, China

and more 140 locations

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2023-10-04
Last Posted Date
2025-04-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
727
Registration Number
NCT06066515
Locations
🇺🇸

Solaris Clinical Research, Meridian, Idaho, United States

🇺🇸

Evanston Premier Healthcare Research LLC, Skokie, Illinois, United States

🇺🇸

Velocity Clinical Research-Valparaiso-68883, Valparaiso, Indiana, United States

and more 115 locations

A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Microgynon®
First Posted Date
2023-06-09
Last Posted Date
2025-04-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT05896384
Locations
🇩🇪

Charité Research Organisation GmbH, Berlin, Germany

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Phase 1
Completed
Conditions
Healthy
Obesity
Interventions
Drug: Placebo
First Posted Date
2023-03-02
Last Posted Date
2025-01-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
88
Registration Number
NCT05751226
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

Phase 1
Completed
Conditions
Healthy
Liver Diseases
Obesity
Interventions
First Posted Date
2022-03-25
Last Posted Date
2024-08-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
82
Registration Number
NCT05296733
Locations
🇸🇰

SUMMIT CLINICAL RESEARCH, s.r.o., Bratislava, Slovakia

🇺🇸

Arizona Liver Health, Chandler, Arizona, United States

🇩🇪

Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

and more 9 locations

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Phase 1
Recruiting
Conditions
Obesity
Interventions
First Posted Date
2022-01-21
Last Posted Date
2024-11-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT05202353
Locations
🇳🇱

Amsterdam UMC, location VUMC, Amsterdam, Netherlands

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Phase 2
Completed
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Drug: Placebo
First Posted Date
2021-02-25
Last Posted Date
2024-12-03
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
295
Registration Number
NCT04771273
Locations
🇺🇸

North Alabama Health Research, LLC, Huntsville, Alabama, United States

🇺🇸

Southern California Research Center, Coronado, California, United States

🇺🇸

Velocity Clinical Research, Panorama City, California, United States

and more 146 locations

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Phase 2
Completed
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2020-12-14
Last Posted Date
2023-11-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
387
Registration Number
NCT04667377
Locations
🇺🇸

Valley Weight Loss Clinic, Fargo, North Dakota, United States

🇦🇺

Nepean Hospital, Kingswood, New South Wales, Australia

🇺🇸

Lucas Research, Inc., Morehead City, North Carolina, United States

and more 40 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy